Two tetravalent architectures, the glycocalix 7 and the RAFT 9, presenting four residues of a GM-3 ganglioside lactone mimetic, target the host compartment of melanoma and significantly abrogate the effect induced by cancerassociated fibroblasts (CAFs) contact + hypoxia in motility and invasiveness of tumor cells. The data reported: support the involvement of glycoshingolipids (GSLs) in hypoxia and show an interesting role played by the compound 9 in targeting melanoma cells thereby interfering with melanoma progression. The unprecedented findings reported for the glycocluster 9 could contribute in shedding light on the understanding of the critical and complex interactions between tumor cells and their local environment paving the way for new therapeutic agents.
Titolo: | Role of a Preorganized Scaffold Presenting Four Residues of a GM-3 Lactone Mimetic on Melanoma Progression |
Autori: | |
Data di pubblicazione: | 2016 |
Rivista: | |
Abstract: | Two tetravalent architectures, the glycocalix 7 and the RAFT 9, presenting four residues of a GM-3 ganglioside lactone mimetic, target the host compartment of melanoma and significantly abrogate the effect induced by cancerassociated fibroblasts (CAFs) contact + hypoxia in motility and invasiveness of tumor cells. The data reported: support the involvement of glycoshingolipids (GSLs) in hypoxia and show an interesting role played by the compound 9 in targeting melanoma cells thereby interfering with melanoma progression. The unprecedented findings reported for the glycocluster 9 could contribute in shedding light on the understanding of the critical and complex interactions between tumor cells and their local environment paving the way for new therapeutic agents. |
Handle: | http://hdl.handle.net/11368/2883609 |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1021/acsmedchemlett.5b00283 |
URL: | http://pubs.acs.org/doi/abs/10.1021/acsmedchemlett.5b00283 |
Appare nelle tipologie: | 1.1 Articolo in Rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
2016_ACS_MedChemLett.pdf | versione editoriale | Documento in Versione Editoriale | Digital Rights Management non definito | Administrator Richiedi una copia |
ACS MedChemLett_Nativi_et al_Rev.pdf | versione post-print | Bozza finale post-referaggio (post-print) | Digital Rights Management non definito | Administrator Richiedi una copia |
ml5b00283_si_001.pdf | Supporting information | Altro materiale allegato | Digital Rights Management non definito | Administrator Richiedi una copia |